Discuss PSEN1 results in short, repeated conversations rather than one sitting, and tie each conversation to what symptoms are doing right now. PSEN1 is a gene linked to early-onset Alzheimer's disease; a test result only has practical meaning for the family when it's paired with a plan for who gets told, what changes medically, and what happens if the picture shifts. Families usually get the result once, from a genetic counselor, and then have to keep re-explaining it for years as a relative's symptoms worsen, new relatives ask questions, or insurance and care decisions come up. Treating the disclosure as a single event is the most common mistake; treating it as an ongoing conversation, revisited at set points, is what genetics guidelines actually recommend.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why a PSEN1 result is not a one-time conversation
- Who actually needs a PSEN1 test, and what the result covers
- Deciding who else in the family needs to know
- Protecting insurance and legal interests before, not after, disclosure
- Frequently Asked Questions
Why a PSEN1 result is not a one-time conversation
Genetic counseling guidelines treat disclosure as the start of a process, not the end of one. The National Society of Genetic Counselors' guideline on Alzheimer's genetic counseling recommends scheduling a follow-up "check-in" with the patient and any participating family member after the initial disclosure, specifically to revisit who the person plans to tell. A 2011 joint predictive-testing guideline, developed with input from Alzheimer's family networks including DIAN, goes further: it requires structured post-test counseling and follow-up, built on a pre-test assessment of how well the person and family are likely to cope, rather than a single disclosure appointment.
That structure matters because reactions don't resolve quickly. A study following people at risk for dominant Alzheimer's mutations found that one year after disclosure, people who tested negative reported distress similar in magnitude to those who tested positive. The distress came from having gone through testing at all, not just from the result itself — which is the reason a structured, repeatable conversation plan helps every family, regardless of what the result says. As symptoms progress, the conversation needs to shift from "what does this mean" to "what does this mean now." A result discussed calmly at diagnosis can feel very different once a relative starts having trouble with daily tasks, and families who planned for a single conversation often find themselves without a next step.
Who actually needs a PSEN1 test, and what the result covers
PSEN1 testing is intended for people with early-onset dementia who have at least one affected family member — it is not a general population screen and not a tool for predicting common, late-onset Alzheimer's, according to PathologyTestsExplained.org.au. Keeping that scope in mind when symptoms progress prevents two common misreadings: assuming a positive result explains every symptom a relative has, or assuming a negative result means the family is free of genetic risk. On the second point, a negative PSEN1 result is not reassurance that the cause is non-genetic. Reference material from laboratory testing sources notes that disease-causing variants are identified in only 60–80% of people with early-onset Alzheimer's disease.
A family with a negative PSEN1 result and a strong early-onset pattern may still be dealing with a genetic cause the current test doesn't catch — a point worth raising directly with a genetic counselor rather than treating the negative result as closing the question. Families should also expect symptoms to look different from what they picture as "typical" Alzheimer's. PSEN1-linked disease commonly causes memory loss and executive dysfunction, but case-series literature documents mutation-specific features including seizures, prosopagnosia (difficulty recognizing faces), movement disorders, or unusually rapid decline. Discussing the result with this range in mind helps a family recognize a new symptom as part of the known disease course rather than an unrelated, alarming development.
Deciding who else in the family needs to know
A PSEN1 result affects relatives who didn't take the test, which is why guidance treats disclosure planning as part of the clinical process. UK clinical guidance from the Royal Free London NHS Foundation Trust recommends giving patients a written results letter they can share with relatives and having a genetic counselor help identify which relatives — typically first- and second-degree family members — should be told as the condition progresses. A few practical points make that conversation easier:.
- A written letter from the testing clinician gives relatives something concrete to reference, rather than a secondhand summary.
- First-degree relatives (parents, siblings, children) and second-degree relatives (grandparents, aunts, uncles, nieces, nephews) are the usual starting list, because they carry meaningful risk themselves.
- Revisiting the "who should know" list isn't a one-time decision — a teenager at the time of disclosure may be an adult making reproductive or career decisions five years later.
- A genetic counselor can help frame the conversation for relatives who weren't present for the original disclosure, so they're not getting the news secondhand and unsupported.
Protecting insurance and legal interests before, not after, disclosure
A PSEN1 result carries financial consequences that are easy to miss in the middle of a medical crisis. The federal Genetic Information Nondiscrimination Act (GINA) protects against genetic discrimination in health insurance and employment, but it explicitly does not cover life, disability, or long-term-care insurance, according to NPR's reporting on the law. That gap means a disclosed PSEN1 result can be used against a family member applying for those policy types.
State protections fill some of that gap, but unevenly. A policy analysis found that only 13 states regulate genetic information in life insurance, 14 in disability insurance, and 11 in long-term-care insurance, while 27 states have no such laws in any of these categories, per GenomeWeb's review. Because of this patchwork, families should raise life, disability, and long-term-care insurance applications with relatives before a PSEN1 result is disclosed to them or to anyone else — once the result is on record, those options may close. This is also the point to ask a genetic counselor directly what the family's specific state does and doesn't cover, since the answer varies widely and changes the order in which disclosure and insurance conversations should happen.
Frequently Asked Questions
Does a negative PSEN1 result rule out a genetic cause of early-onset dementia?
No. Disease-causing variants are found in only 60–80% of early-onset Alzheimer's cases, so a negative result can leave a genetic cause unidentified rather than ruled out.
Should insurance applications happen before or after telling family about a PSEN1 result?
Before. GINA doesn't cover life, disability, or long-term-care insurance, and most states have no law filling that gap, so applying first protects those options.
